Skip to main content

Table 4 Comparison of immunogenicity of 2010-2011 influenza vaccines against H1N1 pdm09 between infection-primed group and vaccine-primed group in the split and subunit vaccine group among children 9-18 years of age

From: The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study

 

IP (n = 32)

VP (n = 145)

P value

Split

 

17

57

 

Mean age

 

12.81 (±2.44)

11.76 (±2.01)

0.077

Seroprotection (%)

Baseline

70.59 (12/17)

52.63 (30/57)

0.098

1 month

94.12 (16/17)

75.44 (43/57)

0.001

6 months

86.67 (13/15)

76.00 (38/50)

0.038

Seroconversion (%)

 

64.71 (11/17)

38.60 (22/57)

0.001

GMT (95 % CI)

Baseline

35.39 (26.93–43.86)

30.61 (23.99–37.24)

0.644

1 month

250.56 (138.16–362.95)

77.13 (66.37–87.90)

0.004

6 months

139.29 (94.10–184.47)

64.09 (53.03–75.14)

0.019

Subunit

 

15

88

 

Mean age

 

12.30 (±2.67)

12.74 (±2.57)

0.544

Seroprotection (%)

Baseline

73.33 (11/15)

60.23 (53/88)

0.345

1 month

93.33 (14/15)

73.86 (65/88)

0.022

6 months

62.5 (5/8)

45.68 (37/81)

0.369

Seroconversion (%)

 

73.33 (11/15)

37.50 (33/88)

0.011

GMT (95 % CI)

Baseline

60.63 (36.22–85.04)

28.28 (23.98–32.59)

0.015

1 month

242.51 (158.95–326.08)

65.70 (51.58–79.82)

0.002

6 months

56.57 (10.48–102.66)

29.05 (23.28–34.82)

0.166